At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action Angiotensin type 1 receptor antagonists; Angiotensin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 18 Nov 1998 No-Development-Reported for Hypertension in USA (PO)
- 24 Jan 1996 New profile
- 24 Jan 1996 Preclinical development for Hypertension in USA (PO)